UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

Journal of thoracic oncology, 2013-03, Vol.8 (3), p.369-372

2013

Volltextzugriff (PDF)

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib

Cancer, 2020-03, Vol.126 (6), p.1339-1350

2020

Volltextzugriff (PDF)

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

Cancer, 2020-08, Vol.126 (16), p.3788-3799

2020

Volltextzugriff (PDF)

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

Cancer research (Chicago, Ill.), 2005-08, Vol.65 (16), p.7052-7058

2005

Volltextzugriff (PDF)

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

Molecular cancer therapeutics, 2013-10, Vol.12 (10), p.2200-2212

2013

Volltextzugriff (PDF)

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

Blood, 2014-05, Vol.123 (21), p.3269-3276

2014

Volltextzugriff (PDF)

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.464-476

2021

Volltextzugriff (PDF)

Apoptosis as a Novel Target for Cancer Chemoprevention

JNCI : Journal of the National Cancer Institute, 2004-05, Vol.96 (9), p.662-672

2004

Volltextzugriff (PDF)

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

Molecular and cellular biology, 2015-07, Vol.35 (13), p.2344-2355

2015

Volltextzugriff (PDF)

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

PloS one, 2019-02, Vol.14 (2), p.e0206309-e0206309

2019

Volltextzugriff (PDF)

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

Journal of translational medicine, 2016-05, Vol.14 (1), p.111-111, Article 111

2016

Volltextzugriff (PDF)

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Cancer letters, 2015-08, Vol.364 (1), p.70-78

2015

Volltextzugriff (PDF)

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

Cancer research (Chicago, Ill.), 2008-09, Vol.68 (18), p.7409-7418

2008

Volltextzugriff (PDF)

Peli1 signaling blockade attenuates congenital zika syndrome

PLoS pathogens, 2020-06, Vol.16 (6), p.e1008538

2020

Volltextzugriff (PDF)

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

Cancer research (Chicago, Ill.), 2009-12, Vol.69 (23), p.8967-8976

2009

Volltextzugriff (PDF)

Corrigendum to “Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E” [Neoplasia, volume 12, issue 10 (2010):848 –855]

Neoplasia (New York, N.Y.), 2024-10, Vol.56, p.101031, Article 101031

2024

Volltextzugriff (PDF)

mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis

Cancer research (Chicago, Ill.), 2013-03, Vol.73 (6), p.1946-1957

2013

Volltextzugriff (PDF)

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition

Oncotarget, 2015-10, Vol.6 (33), p.34669-34679

2015

Volltextzugriff (PDF)

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

PloS one, 2011-06, Vol.6 (6), p.e20899

2011

Volltextzugriff (PDF)

Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation

Cancer research (Chicago, Ill.), 2008-09, Vol.68 (18), p.7484-7492

2008

Volltextzugriff (PDF)

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

Cancer research (Chicago, Ill.), 2007-05, Vol.67 (10), p.4981-4988

2007

Volltextzugriff (PDF)

Cables1 complex couples survival signaling to the cell death machinery

Cancer research (Chicago, Ill.), 2015-01, Vol.75 (1), p.147-158

2015

Volltextzugriff (PDF)

Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

Cancer research (Chicago, Ill.), 2013-09, Vol.73 (17), p.5485-5496

2013

Volltextzugriff (PDF)

p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells

The Journal of clinical investigation, 2010-04, Vol.120 (4), p.1165-1177

2010

Volltextzugriff (PDF)

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

Cancer medicine (Malden, MA), 2014-12, Vol.3 (6), p.1579-1594

2014

Volltextzugriff (PDF)

1 – 25 von 189

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieThe Journal Of Biological Chemistry

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(177)
Mit Volltextzugriff
(187)

Publikationsform

Sprache

Englisch
(189)

Erscheinungsjahr

n.n

Thema

Science & Technology
(126)
Humans
(113)
Life Sciences & Biomedicine
(109)
Oncology
(90)
Cell Line, Tumor
(58)
Lung Neoplasms - Pathology
(49)
Apoptosis - Drug Effects
(48)
Biological And Medical Sciences
(44)
Apoptosis
(41)
Carcinoma, Non-Small-Cell Lung - Pathology
(40)
Medical Sciences
(39)
Lung Neoplasms - Metabolism
(38)
Antineoplastic Agents - Pharmacology
(36)
Tumors
(33)
Antineoplastic Agents
(32)
Pharmacology. Drug Treatments
(31)
Animals
(30)
Lung Neoplasms - Drug Therapy
(30)
Carcinoma, Non-Small-Cell Lung - Metabolism
(29)
Lung Cancer
(27)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase II Study of Docetaxel in Combination with Everolimus for Second- or Third-Line Therapy of Advanced Non–Small-Cell Lung Cancer

ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor‐mutant non–small cell lung cancer cells to osimertinib

MEK or ERK inhibition effectively abrogates emergence of acquired osimertinib resistance in the treatment of epidermal growth factor receptor–mutant lung cancers

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition

Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer

MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells

YAP1 Expression in SCLC Defines a Distinct Subtype With T-cell–Inflamed Phenotype

Apoptosis as a Novel Target for Cancer Chemoprevention

mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation

Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models

Patient-derived xenografts faithfully replicated clinical outcome in a phase II co-clinical trial of arsenic trioxide in relapsed small cell lung cancer

Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells

Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation

Peli1 signaling blockade attenuates congenital zika syndrome

Perifosine Inhibits Mammalian Target of Rapamycin Signaling through Facilitating Degradation of Major Components in the mTOR Axis and Induces Autophagy

Corrigendum to “Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E” [Neoplasia, volume 12, issue 10 (2010):848 –855]

mTOR Complex 2 Is Involved in Regulation of Cbl-Dependent c-FLIP Degradation and Sensitivity of TRAIL-Induced Apoptosis

The BET bromodomain inhibitor, JQ1, facilitates c-FLIP degradation and enhances TRAIL-induced apoptosis independent of BRD4 and c-Myc inhibition

The combination of RAD001 and NVP-BEZ235 exerts synergistic anticancer activity against non-small cell lung cancer in vitro and in vivo

Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

Cables1 complex couples survival signaling to the cell death machinery

Novel Small-Molecule Inhibitors of Bcl-XL to Treat Lung Cancer

p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human head and neck squamous cell carcinoma cells

Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer

Aktive Filter

Suchergebnisse filtern